Meeting Abstract


DOI :10.26650/JARHS2021-1134059   IUP :10.26650/JARHS2021-1134059    Full Text (PDF)

PRECISION MEDICINE IN NEUROBLASTOMA: EXPERIENCE WITH NEXT GENERATION SEQUENCING

Tekincan Çağrı AktaşDeniz KızmazoğluSafiye AktaşÖzde GökbayrakEmre ÇeçenDilek İnceZekiye AltunNur Olgun

Objectives: The objective of this study is to examine neuroblastoma patients that were examined by next generation sequencing (NGS) for targeted therapy related specific gene mutations including Anaplastic Lymphoma Kinase (ALK) Materials and Methods: Molecular examinations of neuroblastoma according to Turkish Pediatric Oncology Group protocols (Nmyc amplification, 11q23 deletion, 1p36 deletion, DNA ploidy by Cell cycle kit in flow cytometer) is studied in our department in all cases collected from Turkey. Among these cases, the patients that recurred even after multi model therapies, are requested NGS to evaluate for targeted therapy decision. We study single nucleated variations after DNA isolation using Pillar Onco/Reveal Multicancer v4 with CNV Panel with 60 genes (ALK, BRAF, ERB2, PIK3CA, EGFR, KRAS, MET, ….) on İllumina Miniseq platform. Results: We especially reported ALK mutations which has indication for crizotinib or alectinib. Out of our investigated patients only 22% (9/41) had ALK mutations. Two patients (22%) had R1275Q mutation, six patients (66,7%) had F1174L mutation and one patient (11%) had L1226F, S1189F, V1135A and G1225S mutations. Conclusion: Our patient cohort seems to be showing ALK mutations and F1174L (sensitive to alectinib) mutation more often than R1275Q mutation (sensitive to crizotinib) in neuroblastoma cases. The reason that ALK mutation ratio is higher than literature. The reason of this might be because of selection of patients by the clinicians. These patients received targeted therapies and had longer survival.


PDF View

References

    Citations

    Copy and paste a formatted citation or use one of the options to export in your chosen format


    EXPORT



    APA

    Aktaş, T.Ç., Kızmazoğlu, D., Aktaş, S., Gökbayrak, Ö., Çeçen, E., İnce, D., Altun, Z., & Olgun, N. (2022). PRECISION MEDICINE IN NEUROBLASTOMA: EXPERIENCE WITH NEXT GENERATION SEQUENCING. Journal of Advanced Research in Health Sciences, 5(1), 40-40. https://doi.org/10.26650/JARHS2021-1134059


    AMA

    Aktaş T Ç, Kızmazoğlu D, Aktaş S, Gökbayrak Ö, Çeçen E, İnce D, Altun Z, Olgun N. PRECISION MEDICINE IN NEUROBLASTOMA: EXPERIENCE WITH NEXT GENERATION SEQUENCING. Journal of Advanced Research in Health Sciences. 2022;5(1):40-40. https://doi.org/10.26650/JARHS2021-1134059


    ABNT

    Aktaş, T.Ç.; Kızmazoğlu, D.; Aktaş, S.; Gökbayrak, Ö.; Çeçen, E.; İnce, D.; Altun, Z.; Olgun, N. PRECISION MEDICINE IN NEUROBLASTOMA: EXPERIENCE WITH NEXT GENERATION SEQUENCING. Journal of Advanced Research in Health Sciences, [Publisher Location], v. 5, n. 1, p. 40-40, 2022.


    Chicago: Author-Date Style

    Aktaş, Tekincan Çağrı, and Deniz Kızmazoğlu and Safiye Aktaş and Özde Gökbayrak and Emre Çeçen and Dilek İnce and Zekiye Altun and Nur Olgun. 2022. “PRECISION MEDICINE IN NEUROBLASTOMA: EXPERIENCE WITH NEXT GENERATION SEQUENCING.” Journal of Advanced Research in Health Sciences 5, no. 1: 40-40. https://doi.org/10.26650/JARHS2021-1134059


    Chicago: Humanities Style

    Aktaş, Tekincan Çağrı, and Deniz Kızmazoğlu and Safiye Aktaş and Özde Gökbayrak and Emre Çeçen and Dilek İnce and Zekiye Altun and Nur Olgun. PRECISION MEDICINE IN NEUROBLASTOMA: EXPERIENCE WITH NEXT GENERATION SEQUENCING.” Journal of Advanced Research in Health Sciences 5, no. 1 (Feb. 2024): 40-40. https://doi.org/10.26650/JARHS2021-1134059


    Harvard: Australian Style

    Aktaş, TÇ & Kızmazoğlu, D & Aktaş, S & Gökbayrak, Ö & Çeçen, E & İnce, D & Altun, Z & Olgun, N 2022, 'PRECISION MEDICINE IN NEUROBLASTOMA: EXPERIENCE WITH NEXT GENERATION SEQUENCING', Journal of Advanced Research in Health Sciences, vol. 5, no. 1, pp. 40-40, viewed 24 Feb. 2024, https://doi.org/10.26650/JARHS2021-1134059


    Harvard: Author-Date Style

    Aktaş, T.Ç. and Kızmazoğlu, D. and Aktaş, S. and Gökbayrak, Ö. and Çeçen, E. and İnce, D. and Altun, Z. and Olgun, N. (2022) ‘PRECISION MEDICINE IN NEUROBLASTOMA: EXPERIENCE WITH NEXT GENERATION SEQUENCING’, Journal of Advanced Research in Health Sciences, 5(1), pp. 40-40. https://doi.org/10.26650/JARHS2021-1134059 (24 Feb. 2024).


    MLA

    Aktaş, Tekincan Çağrı, and Deniz Kızmazoğlu and Safiye Aktaş and Özde Gökbayrak and Emre Çeçen and Dilek İnce and Zekiye Altun and Nur Olgun. PRECISION MEDICINE IN NEUROBLASTOMA: EXPERIENCE WITH NEXT GENERATION SEQUENCING.” Journal of Advanced Research in Health Sciences, vol. 5, no. 1, 2022, pp. 40-40. [Database Container], https://doi.org/10.26650/JARHS2021-1134059


    Vancouver

    Aktaş TÇ, Kızmazoğlu D, Aktaş S, Gökbayrak Ö, Çeçen E, İnce D, Altun Z, Olgun N. PRECISION MEDICINE IN NEUROBLASTOMA: EXPERIENCE WITH NEXT GENERATION SEQUENCING. Journal of Advanced Research in Health Sciences [Internet]. 24 Feb. 2024 [cited 24 Feb. 2024];5(1):40-40. Available from: https://doi.org/10.26650/JARHS2021-1134059 doi: 10.26650/JARHS2021-1134059


    ISNAD

    Aktaş, TekincanÇağrı - Kızmazoğlu, Deniz - Aktaş, Safiye - Gökbayrak, Özde - Çeçen, Emre - İnce, Dilek - Altun, Zekiye - Olgun, Nur. PRECISION MEDICINE IN NEUROBLASTOMA: EXPERIENCE WITH NEXT GENERATION SEQUENCING”. Journal of Advanced Research in Health Sciences 5/1 (Feb. 2024): 40-40. https://doi.org/10.26650/JARHS2021-1134059



    TIMELINE


    Published Online09.08.2022

    LICENCE


    Attribution-NonCommercial (CC BY-NC)

    This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


    SHARE




    Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.